

## Capital Group New World Fund (AU)

### Market review

- Global stocks advanced as the rollout of coronavirus vaccines and additional government stimulus measures boosted investor sentiment across the board. All major sectors in the MSCI World Index generated positive returns, reflecting a brighter outlook for the global economy. Gains were tempered by rising COVID-19 outbreaks, prompting new lockdowns in some countries.
- U.S. equities soared as multiple COVID-19 vaccines were approved, and Congress agreed on a coronavirus relief package. A US\$900 billion stimulus bill was passed to help offset some of the pandemic's economic impact. The U.S. economy had grown at an annualized 33.4% in the third quarter, but the subsequent spike in infections threatened to slow the recovery.
- European stocks rallied. Facing a December 31 deadline, Brexit negotiators hammered out a broad agreement governing the United Kingdom's new trading relationship with the European Union. The announcement sent the British pound soaring as the threat of a "no-deal Brexit" – which would result in a reversion to less favorable rules under the World Trade Organization – was narrowly avoided in the final days of 2020.
- Emerging markets stocks posted their strongest quarterly returns in more than a decade, boosted by China's economic rebound, stronger commodity prices and a weaker dollar. Stocks in China advanced as the country's economy rebounded. Some of the biggest gains came from providers of internet services platforms. Elsewhere, Brazil's economy bounced back in the third quarter, growing 7.7% compared with the April-to-June period. Overall, commodity-exporting Latin American countries posted strong quarterly returns after lagging most Asian countries earlier in 2020.

### Three-month portfolio review

- For the three months ended 31 December 2020, Capital Group New World Fund (AU) returned 11.5%<sup>1</sup> before fees and 11.2%<sup>2</sup> net of fees, while the index returned 11.2%.<sup>3</sup> For the 12-month period, the fund returned 14.6%<sup>1</sup> before fees and 13.3%<sup>2</sup> net of fees, while the index returned 7.8%.<sup>3</sup>
- The selection of stocks and a low relative position in the consumer discretionary sector proved positive. Relatively low exposure to **Alibaba Group** helped, as shares declined 21%. Shares came under pressure from tightening regulation and the forced suspension of the planned initial public offering for Alibaba's online banking service, Ant Group. Alibaba was compelled to shelve the IPO as Beijing reconsidered the wider role of fintechs in its financial system. Alibaba's stock was additionally hampered after the Chinese authorities unveiled new rules to curb monopolistic practices in the domestic internet industry.
- Stock selection in and, to a lesser extent, a relatively low exposure to, the communication services sector also contributed to relative returns. A relatively light exposure to China-based internet-services conglomerate **Tencent Holdings** was beneficial as the company's shares lagged the broader market's strength despite reporting better-than-expected third-quarter earnings. Investors were concerned about the impact of new antitrust regulations in China.

- Stock selection in the information technology sector proved negative. Relatively low exposure to **Samsung Electronics** hurt. The maker of memory chips and electronics reported a strong quarterly profit, the result of emergency chip orders from Huawei and broader demand from China. The company's operating margin increased substantially as it benefitted from an improved product mix. Encouraging news on COVID-19 vaccines raised hopes that demand across the smartphone market could accelerate in 2021, while accelerating uptake of 5G technology could help demand for semiconductors.
- Stock selection in, and a relatively high exposure to, the health care sector detracted from relative returns. A position in **AstraZeneca** detracted as its shares fell amid worries that regulatory approval for its COVID-19 vaccine could be delayed owing to controversy over clinical trial results and concerns that it was overpaying to acquire rare diseases and immunology specialist Alexion Pharmaceuticals in a US\$39 billion deal. However, at the end of December, the UK medicines regulator approved the AstraZeneca-Oxford vaccine.

Index returns are shown in US dollar terms while stock returns are total returns as shown in local currency terms, unless otherwise stated. Sources: Capital Group, MSCI

<sup>1</sup> Returns are before management fees and expenses, in Australian dollar terms. Source: Capital Group

<sup>2</sup> Returns are net of fees at maximum management fee, in Australian dollar terms. Source: Capital Group

<sup>3</sup> MSCI Emerging Markets Index, with net dividends reinvested, in Australian dollar terms. Source: MSCI

All information current as at the last business day of month of report unless otherwise noted. This communication contains sensitive and confidential information. Any use for any other purpose, and disclosure, dissemination, copying, reproduction or distribution of the information is prohibited. This communication is intended for professional investors only and should not be relied upon by retail investors. Past results are not predictive of future results. This information is neither an offer nor a solicitation to buy or sell any securities or to provide any investment service. While Capital Group uses reasonable efforts to obtain information from third-party sources which it believes to be reliable, Capital Group makes no representation or warranty as to the accuracy, reliability or completeness of the information. This communication is of a general nature, it is not intended to be comprehensive or to provide investment, tax or other advice. It has been prepared for multiple distributions and does not take account of the specific investment objectives of individual recipients and it may not be appropriate in all circumstances. This communication has been prepared by Capital International, Inc., a member of Capital Group, a company incorporated in California, United States of America. The liability of members is limited. In Australia, this communication and Capital Group New World Fund (AU) (ARSN: 616 311 516) are issued by Capital Group Investment Management Limited (ACN 164 174 501 AFSL No. 443 118), a member of Capital Group, located at Level 18, 56 Pitt Street, Sydney NSW 2000 Australia. The said fund is offered only by Product Disclosure Statement (PDS), please read the PDS which is available upon request or at [www.thecapitalgroup.com.au](http://www.thecapitalgroup.com.au) in its entirety before making an investment decision. All Capital Group trademarks are owned by The Capital Group Companies, Inc. or an affiliated company in the U.S., Australia and other countries. All other company and product names mentioned are the trademarks or registered trademarks of their respective companies. © 2021 Capital Group. All rights reserved.